California Healthcare Institute Board Elects New Members
New members from PwC, The Scripps Research Institute, Latham & Watkins and Thermo Fisher Scientific strengthen current board
La Jolla, Calif. (PRWEB) July 17, 2013
California Healthcare Institute (CHI) announced today the election of four senior executives to serve on its board of directors: Peter Claude, partner at PwC US; Dr. Michael Marletta, president and CEO of The Scripps Research Institute (TSRI); Alan Mendelson, partner at Latham & Watkins; and Dr. Marc Tremblay, president, clinical diagnostics division at Thermo Fisher Scientific. CHI is a non-profit, public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
“We are delighted to welcome strong new representation from PwC, The Scripps Research Institute, Latham & Watkins and Thermo Fisher Scientific to our board of directors,” said CHI President and CEO David L. Gollaher, Ph.D. “These individuals and the institutions they represent reflect the best of California’s biomedical community and they will help shape our approach to the critical issues affecting the industry, including federal funding for basic research; regulatory challenges; coverage and payment changes; and the business environment in California.”
Claude is a partner in the San Francisco office of PwC, where he leads the company’s pharmaceutical and life science practice serving Northern California. Claude’s clients have included a broad range of large and small domestic and multinational pharmaceutical, biotechnology and medical device manufacturers as well as pharmacy benefit managers. Additionally, he was the principal author of “Recapturing the Vision,” PwC’s groundbreaking study on improving the pharmaceutical industry’s reputation and of two published studies on compliance issues in the medical device industry. Claude holds a Bachelor of Business Administration degree from the University of Notre Dame.
Marletta is president and CEO of The Scripps Research Institute (TSRI). He received a Bachelor of Arts degree in biology and chemistry from SUNY, College at Fredonia and a Ph.D. degree from the University of California, San Francisco, which he followed with a two-year postdoctoral appointment at M.I.T. He was on the faculty at M.I.T. and then the University of Michigan. While at Michigan, he was appointed to the Howard Hughes Medical Institute. Marletta moved to the University of California, Berkeley in 2001 with appointments in Chemistry and MCB. In 2002 he was named the Aldo DeBenedictis Distinguished Professor of Chemistry in 2002. He served as Chair of the Department of Chemistry from 2005-2010. In July 2011 he joined the faculty of The Scripps Research Institute and was named President-Elect and Cecil and Ida Green Professor of Chemistry. He assumed the presidency in January 1, 2012. Marletta has been recognized with: a MacArthur Fellowship (1995), election to the Institute of Medicine (1999), the American Academy of Arts and Sciences (2001) and the National Academy of Sciences (2006). He also has received the Harrison Howe Award (2004), the Repligen Award (2006) and the Esselen Award for Chemistry in the Public Interest (2006).
Mendelson has been a partner in the Silicon Valley office of Latham & Watkins since May 2000 and is the co-chair of the firm’s Emerging Companies Practice and Life Sciences Industry Groups. Mendelson has handled and supervised a variety of major business transactions, including venture capital financings, private placements and public offerings, mergers and acquisitions, joint ventures, and other strategic collaborations and commercial transactions primarily within the life sciences industry. Mendelson is a well-known and established philanthropist and volunteer in the California higher education, healthcare and biotech communities. He has served as President of the Cal Alumni Association and as a member of the Board of Regents of the University of California and currently serves as a member of the the Board of Trustees of The Scripps Research Institute, the Board of Trustees of the UC Berkeley Foundation, the Board of Advisors for the UC Berkeley College of Chemistry and as a member of the Board of the American Friends of the Rambam Medical Center in Haifa, Israel. In addition, Mendelson has served on the board of directors of the Biotechnology Industry Organization (BIO) and is currently a member of the BayBio Board of Directors. Previously, Mendelson served as the President of the National Kidney Foundation of Northern California, Inc. and as a member of the Board of Overseers Visiting Committee of Harvard Law School. Mendelson received his law degree from Harvard Law School and his bachelor’s degree from the University of California, Berkeley.
Tremblay is president of the clinical diagnostics division of Thermo Fisher Scientific. He is responsible for driving innovation and growth in the company’s clinical chemistry analyzers and reagents, automation solutions, biomarkers and niche diagnostics businesses. Prior to his current role, Tremblay was vice president and general manager of the company’s portable elemental and molecular analyzer business. Before joining Thermo Fisher in 2009, Tremblay held a number of executive management positions, including senior vice president at DigitalGlobe, vice president at Z Corporation, president and CEO at Syncline and vice president at Virtual Technologies. Tremblay sits on the advisory boards of Skybox Imaging and American Innovative. Tremblay earned his doctorate from Stanford University and his master’s degree in business administration from Harvard University.
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10922262.htm